Regular PCR testing of nasopharyngeal swabs from symptomatic individuals for SARS-CoV-2 virus has become the established method by which health services are managing the COVID-19 pandemic. Businesses such as AstraZeneca have also prioritised voluntary asymptomatic testing to keep workplaces safe and maintain supply of essential medicines to patients. We describe the development of an internal automated SARS-CoV-2 testing programme including the transformative introduction of saliva as an alternative sample type.
All Keywords
【저자키워드】 Molecular medicine, Infection, Diagnosis, 【초록키워드】 Saliva, COVID-19 pandemic, SARS-CoV-2 virus, Medicine, Nasopharyngeal swab, PCR testing, Asymptomatic, SARS-CoV-2 testing, nasopharyngeal swabs, Health services, automated, patients, AstraZeneca, Safe, Health Service, symptomatic individuals, supply, maintain, Regular, symptomatic individual, 【제목키워드】 SARS-CoV-2, Asymptomatic, automated, PCR test, PROTECT,
【저자키워드】 Molecular medicine, Infection, Diagnosis, 【초록키워드】 Saliva, COVID-19 pandemic, SARS-CoV-2 virus, Medicine, Nasopharyngeal swab, PCR testing, Asymptomatic, SARS-CoV-2 testing, nasopharyngeal swabs, Health services, automated, patients, AstraZeneca, Safe, Health Service, symptomatic individuals, supply, maintain, Regular, symptomatic individual, 【제목키워드】 SARS-CoV-2, Asymptomatic, automated, PCR test, PROTECT,
SARS-CoV-2 바이러스에 대한 증상이 있는 개인의 비인두 면봉에 대한 정기적인 PCR 검사는 의료 서비스가 COVID-19 대유행을 관리하는 확립된 방법이 되었습니다. AstraZeneca와 같은 기업은 작업장을 안전하게 유지하고 환자에게 필수 의약품 공급을 유지하기 위해 자발적인 무증상 검사를 우선시했습니다. 우리는 대체 샘플 유형으로 타액의 변형 도입을 포함하여 내부 자동화된 SARS-CoV-2 테스트 프로그램의 개발을 설명합니다.